OBJECTIVES: Gilbert's syndrome is a congenital, nonhemolytic, unconjugated hyperbilirubinemia. The most common genotype of Gilbert's syndrome is the homozygous polymorphism, A(TA)7TAA, in the promoter of the gene for UDP-glucuronosyltransferase 1A1 (UGT1A1), with a thymine adenine insertion in the TATA-box-like sequence, which results in a decrease in UGT1A1 activity. The mechanism responsible for this decrease in UGT1A1 activity, however, has not been elucidated. To clarify the mechanism underlying this deficiency in UGT1A1 activity in patients with Gilbert's syndrome. METHODS: The promoter activity assay using the wild-type A(TA)6TAA or the mutant A(TA)7TAA promoter and a luciferase reporter was performed in two different hepatoma cell lines. The binding affinity for a nuclear protein complex or for TATA-binding protein was evaluated by a competitive electophoretic mobility shift assay using wild-type or mutant TATA-box-like oligonucleotide probes and nuclear extract or TATA-binding protein. The formation of complexes between TATA-binding protein and wild-type or mutant oligonucleotide probes was also studied by a quantitive electophoretic mobility shift assay. RESULTS: A TA insertion in the TATA-box-like sequence of the promoter activity of UGT1A1 gene. A competitive electrophoretic mobility shift assay showed a decrease in nuclear protein complex binding affinity and TATA-binding protein binding affinity of the mutant TATA-box-like sequence A(TA)7TAA. When the mutants A(TA)5TAA and A(TA)8TAA were also compared, quantitative electrophoretic mobility shift assay demonstrated that the TATA-binding protein binding affinity progressively decreased as the number of TA repeats in the TATA-box-like sequence increased. CONCLUSION: TA insertion in the TATA-box-like sequence of the UGT1A1 promoter affected its binding affinity for TATA-binding protein, causing a decrease in its activity. This explains the pathogenesis of Gilbert's syndrome.
OBJECTIVES:Gilbert's syndrome is a congenital, nonhemolytic, unconjugated hyperbilirubinemia. The most common genotype of Gilbert's syndrome is the homozygous polymorphism, A(TA)7TAA, in the promoter of the gene for UDP-glucuronosyltransferase 1A1 (UGT1A1), with a thymine adenine insertion in the TATA-box-like sequence, which results in a decrease in UGT1A1 activity. The mechanism responsible for this decrease in UGT1A1 activity, however, has not been elucidated. To clarify the mechanism underlying this deficiency in UGT1A1 activity in patients with Gilbert's syndrome. METHODS: The promoter activity assay using the wild-type A(TA)6TAA or the mutant A(TA)7TAA promoter and a luciferase reporter was performed in two different hepatoma cell lines. The binding affinity for a nuclear protein complex or for TATA-binding protein was evaluated by a competitive electophoretic mobility shift assay using wild-type or mutant TATA-box-like oligonucleotide probes and nuclear extract or TATA-binding protein. The formation of complexes between TATA-binding protein and wild-type or mutant oligonucleotide probes was also studied by a quantitive electophoretic mobility shift assay. RESULTS: A TA insertion in the TATA-box-like sequence of the promoter activity of UGT1A1 gene. A competitive electrophoretic mobility shift assay showed a decrease in nuclear protein complex binding affinity and TATA-binding protein binding affinity of the mutant TATA-box-like sequence A(TA)7TAA. When the mutants A(TA)5TAA and A(TA)8TAA were also compared, quantitative electrophoretic mobility shift assay demonstrated that the TATA-binding protein binding affinity progressively decreased as the number of TA repeats in the TATA-box-like sequence increased. CONCLUSION: TA insertion in the TATA-box-like sequence of the UGT1A1 promoter affected its binding affinity for TATA-binding protein, causing a decrease in its activity. This explains the pathogenesis of Gilbert's syndrome.
Authors: Rick J Jansen; Dennis P Robinson; Rachael Z Stolzenberg-Solomon; William R Bamlet; XiangLin Tan; Julie M Cunningham; Ying Li; David N Rider; Ann L Oberg; Kari G Rabe; Kristin E Anderson; Rashmi Sinha; Gloria M Petersen Journal: Pancreas Date: 2013-10 Impact factor: 3.327
Authors: Rohan Gurjar; Laura Dickinson; Daniel Carr; Wolfgang Stöhr; Stefano Bonora; Andrew Owen; Antonio D'Avolio; Adam Cursley; Nathalie De Castro; Gerd Fätkenheuer; Linos Vandekerckhove; Giovanni Di Perri; Anton Pozniak; Christine Schwimmer; François Raffi; Marta Boffito Journal: Pharmacogenomics J Date: 2022-10-20 Impact factor: 3.245
Authors: Misty R Saracino; Jeannette Bigler; Yvonne Schwarz; Jyh-Lurn Chang; Shiuying Li; Lin Li; Emily White; John D Potter; Johanna W Lampe Journal: J Nutr Date: 2009-01-13 Impact factor: 4.798
Authors: R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas Journal: Clin Pharmacol Ther Date: 2015-11-09 Impact factor: 6.875
Authors: Andrea S Blevins-Primeau; Dongxiao Sun; Gang Chen; Arun K Sharma; Carla J Gallagher; Shantu Amin; Philip Lazarus Journal: Cancer Res Date: 2009-02-24 Impact factor: 12.701
Authors: Ai-Ching Boon; Clare L Hawkins; Kavita Bisht; Jeff S Coombes; Bhavisha Bakrania; Karl-Heinz Wagner; Andrew C Bulmer Journal: Free Radic Biol Med Date: 2012-04-14 Impact factor: 7.376